Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim AnalysisJordan Gauthier, Aya Albittar, Andrew J. Portuguese et al.|Blood|2023Cited by 2
Planned Interim Analysis of a Phase 2 Investigator-Initiated Trial of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene MaraleucelEmily C. Liang, Jordan Gauthier, Qian Wu et al.|Transplantation and Cellular Therapy|2024Cited by 2
Phase 2 Trial of SC Versus IV Anakinra to Prevent CRS and Neurotoxicity in LBCL Patients Receiving Lisocabtagene Maraleucel: Final Analysis and Comparison to Historical ControlEmily C. Liang, Jordan Gauthier, Jennifer J. Huang et al.|Transplantation and Cellular Therapy|2025Cited by 0